| __timestamp | BioCryst Pharmaceuticals, Inc. | Cytokinetics, Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 17268000 |
| Thursday, January 1, 2015 | 13047000 | 19667000 |
| Friday, January 1, 2016 | 11253000 | 27823000 |
| Sunday, January 1, 2017 | 13933000 | 36468000 |
| Monday, January 1, 2018 | 29514000 | 31282000 |
| Tuesday, January 1, 2019 | 37121000 | 39610000 |
| Wednesday, January 1, 2020 | 67929000 | 52820000 |
| Friday, January 1, 2021 | 118818000 | 96803000 |
| Saturday, January 1, 2022 | 159371000 | 177977000 |
| Sunday, January 1, 2023 | 213894000 | 173612000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, managing costs is crucial for success. Over the past decade, BioCryst Pharmaceuticals, Inc. and Cytokinetics, Incorporated have demonstrated distinct strategies in handling their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, BioCryst's SG&A expenses surged by an impressive 2,768%, peaking at $213.9 million in 2023. Meanwhile, Cytokinetics saw a more modest increase of 905%, reaching $173.6 million in the same year. This divergence highlights BioCryst's aggressive expansion and investment in administrative capabilities, while Cytokinetics maintained a more conservative approach. Understanding these trends offers valuable insights into each company's operational priorities and strategic direction. As the biotech industry continues to evolve, monitoring such financial metrics will be key to predicting future growth trajectories.
AbbVie Inc. and Cytokinetics, Incorporated: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Catalent, Inc. vs Cytokinetics, Incorporated
Selling, General, and Administrative Costs: Exelixis, Inc. vs BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs Cytokinetics, Incorporated
SG&A Efficiency Analysis: Comparing Cytokinetics, Incorporated and Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and Geron Corporation
Cytokinetics, Incorporated or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Arrowhead Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
ImmunityBio, Inc. vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.